Jim Cramer's Stop Trading: Regeneron Investors Should Not Freak Out

NEW YORK (TheStreet) -- On CNBC's "Cramer's Stop Trading" segment, TheStreet's Jim Cramer, co-manager of the Action Alerts PLUS portfolio, said trading on the last day of the quarter can be tough, since fund managers are doing a lot of juggling with their positions. 

Must Read: 10 Stocks George Soros Is Buying

Specifically, he pointed to Regeneron (REGN) , which reported positive Phase 2 results for its chronic sinusitis drug, Dupilumab. The company is partnered with Sanofi (SNY) for this drug. 

The results, which can also be helpful in treating asthma and atopic dermatitis, should have shares of Regeneron higher by $10. However, since the overall biotech sector is lower due to it being the last day of the quarter, the stock is not reacting the same, Cramer reasoned. 

Investors shouldn't "freak out" because of the price action. It will be fine once the fourth quarter begins. Cramer said he expects the stock market to be strong next quarter, as more money continues to come into U.S. equities. 

-- Written by Bret Kenwell in Petoskey, Mich.

Follow @BretKenwell

At the time of publication, Cramer's Action Alerts PLUS had no position in companies mentioned.

If you liked this article you might like

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Handling Your Finances at Any Age: Cramer's 'Mad Money' Recap (Monday 2/12/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Volatility Reigns Supreme: Cramer's 'Mad Money' Recap (Thursday 2/8/18)

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Anthem, A.O. Smith, Tableau Software: 'Mad Money' Lightning Round

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)

Cramer Calls It a Market Reset: 'Mad Money' Recap (Monday 2/5/18)